Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study

NCT07514052 · clinicaltrials.gov ↗

RECRUITING

Status

127

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma of Bone

Interventions

DRUG: Selinexor-Based Regimen

Sponsor

Shanxi Bethune Hospital